The year 2022-23 has been an excellent year in terms of turnover and profit. The year has generated a turnover of Rs. 223.23 Crore and Profit before Tax of Rs. 29.49 Crore. The Company had sustained the growth during the period of COVID, but the impact of the declining trend of COVID related medicines requirements, across the country which formed a substantial part during the preceding years, has affected our performance both in the form of turnover and profit as compared to the year 2021-22.

The company has recommended payment of dividend during 2023-24 for the year 2023 at 30% of Profit after Tax or 5% Networth whichever is higher and paid dividend which has been apportioned to Rs. 6.29 Crore to Government of India (Bharat Kosh) and Rs. 0.12 Crore to M/s KMVN Ltd (Government of Uttarakhand). IMPCL has also paid an amount of Rs. 10.13 Crore as dividend to its Share Holders during 2022-23 for the year 2021-22.

   The recent development in the performance of the organisation, provided an opportunity to strengthen the financials capabilities. The Net-Worth of the company almost doubled from the 2019-20 valuation of Rs. 75.02 Crore to 128.16 Crore in the year 2022-23. Similarly the Reserves and Surplus increased from Rs. 24.04 to Rs. 76.18 Crore in the year 2022-23. This strengthens the Companies Financials with better Fund Flows, to meet the Working Capital requirement from internal resources without resorting to the over Draft facility. The Capacity Utilisation of the Company also increased from 33.08% in 2019-20 to 73.83% in 2022-23.

    IMPCL having been conferred with WHO-GMP/CoPP certification by DCG(I) for 18 Ayurvedic Products, has given an opportunity to explore the Export Business. IMPCL is under process to commence the export business shortly. IMPCL has established its business diversification plans in the area of Ayurvedic Veterinary medicines and has executed its order on the same. With the implementation of the Government e-Marketplace (GeM), IMPCL has started getting substantial orders through this platform and this has also been accepted by various Government Institutions.

    With our strong commitment and unmatched product portfolio, we have been effectively managing our business, regardless of the operating environment and relentlessly working towards Goals set for ourselves.


(Dr. Mukesh Kumar)

Managing Director

Last Updated on : 21/10/2023